Recent News

• 04.21.2025 - Applied DNA’s LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
• 04.08.2025 - Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
• 04.01.2025 - Applied DNA Positions TR8 PGx Testing Service as Pre-emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
• 03.26.2025 - Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test
• 03.12.2025 - Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025
• 02.13.2025 - Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress
• 02.12.2025 - Applied DNA to Report First Quarter Fiscal 2025 Financial Results
• 02.11.2025 - APDN Reminds Shareholders to Vote Ahead of Special Meeting on February 14
• 02.11.2025 - APDN Reminds Shareholders to Vote Ahead of Special Meeting on February 14

Recent Filings

• 04.15.2025 - DEF 14A Other definitive proxy statements
• 04.08.2025 - 8-K Current report
• 04.04.2025 - PRE 14A Other preliminary proxy statements
• 04.01.2025 - 8-K Current report
• 03.12.2025 - EX-99.1 EX-99.1
• 03.12.2025 - 8-K Current report
• 02.28.2025 - 8-K Current report
• 02.14.2025 - 8-K Current report
• 02.13.2025 - 8-K Current report
• 02.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]